Blue Cross Blue Shield of Michigan and Oncology Physician Resource have launched an oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource have launched an oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
The Michigan Oncology Clinical Treatment Pathways program includes up-to-date clinical guidelines for treating patients with lung, breast and colon cancer, as well as guidelines for supportive care. Supportive care products are used to prevent or treat the adverse side effects that arise as a result of the tumor itself or administration of cancer treatment. The guidelines will be shared with oncologists across Michigan.
“The program was initially introduced in September 2009 at the annual Michigan Society of Hematology and Oncology (MSHO) meeting,” says Tom Simmer, MD, chief medical officer at Blue Cross Blue Shield of Michigan. “Regional workshops are taking place and will include material dissemination and individual Q&A sessions. Additional Web conferences were also made available. The Coordinating Center is also introducing the Pathways Program to Michigan oncologists through in-person meetings, mail distribution of program materials and electronically via a Web portal.”
P4 Healthcare, creators of the P4 Pathways program that serves as the foundation for this initiative, will provide technology, tools, expertise, educational programs and hands-on training for developing, implementing, monitoring and reporting on anything relating to the P4 Pathways program.
“This initiative is part of our Physician Group Incentive Program, a partnership between the Blues and Michigan physicians,” says Simmer. “Oncologists share guidelines, findings and other information through meetings, seminars, and written communication. We expect measurable results about one year after the guideline process is implemented. Over time additional information related to clinical outcomes will be available and communicated to the public.”
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More